Inspection Record

Southern Tier Home Infusion, Inc. dba Pharmacy Innovations — FDA 483 Findings

US FDAInspected 2022-11-30Published 2023-01-30 9 findingsAseptic processing and sterility assuranceEquipment and facilityOther quality system

Inspectors Jazmine N. BrownThe inspectors who signed the published document.Inspector lookup

View the regulator's official source The source document is always the basis for judgement.

Findings

1Aseptic processing and sterility assurance

Media fills were not performed that closely simulated aseptic production operations incorporating, as appropriate, worst-case activities and conditions that provide a challenge to aseptic operations.

2Aseptic processing and sterility assurance

Disinfecting agents and cleaning wipes used in the ISO 5 area aseptic processing areas are not sterile.

3Equipment and facility

The facility design was observed to allow the influx of poor quality air into higher classified area.

4Other quality system

(D) ( 4) and then cleaning the work surfaces and equtpment insiac of the ISO 5 LAFW bench area.

5Equipment and facility

The ISO-classified areas have difficult to clean, particle-generating, or visibly dirty equipment or surfaces.

6Aseptic processing and sterility assurance

Biological indicators were not used to verify the adequacy of the sterilization cycle.

7Aseptic processing and sterility assurance

Environmental monitoring was not performed in your aseptic processing areas.

8Aseptic processing and sterility assurance

Personnel were observed conducting aseptic manipulations or placing equipment/supplies in an area that blocked the movement of first pass air around uncapped syringes, whether before or after it is filled with sterile product.

9Aseptic processing and sterility assurance

Your firm failed to perform adequate smoke studies under dynamic conditions to demonstrate unidirectional airflow within the ISO 5 area.

About this record

Extracted automatically from the document US FDA published on 2023-01-30. The source is available at the link above.

This is a record of that moment. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out. Do not read it as the current state; check the regulator's official announcements for the latest status.

Translation and classification are automated and may differ in nuance from the source.

Other records for this company

Southern Tier Home Infusion, Inc. dba Pharmacy Innovations findings history — including this company's other documents US FDA documents, 2023 Go to Findings search